Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP-PCI: Early Heparin in STEMI
NCT05329155Completed
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: TIMI 3 flow of the infarct related artery before PPCI at 2 hours. Started Jul 2022; status: completed.
02
Drugs
heparin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05329155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329155.